Search Results - Ts-Ting Lin
- Showing 1 - 3 results of 3
-
1
-
2
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development by Yun‐Chieh Sung, Ya-Chi Liu, Po‐Han Chao, Chih-Chun Chang, Pei-Ru Jin, Ts-Ting Lin, Ja-An Lin, Hui‐Teng Cheng, Jane Wang, Charles Pin‐Kuang Lai, Ling-Hsuan Chen, Anthony Yan-Tang Wu, Ting-Lun Ho, Tsaiyu Chiang, Dongyu Gao, Dan G. Duda, Yunching Chen
Published 2017Artigo -
3
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors by Yunching Chen, Ya-Chi Liu, Yun‐Chieh Sung, Rakesh R. Ramjiawan, Ts-Ting Lin, C. S. Chang, Kuo‐Shyang Jeng, Chiung-Fang Chang, Chun-Hung Liu, Dong-Yu Gao, Fu‐Fei Hsu, Annique M. Duyverman, Shuji Kitahara, Peigen Huang, Simona Dima, Irinel Popescu, Keith T. Flaherty, Andrew X. Zhu, Nabeel Bardeesy, Rakesh K. Jain, Cyril H. Benes, Dan G. Duda
Published 2017Artigo
Search Tools:
Related Subjects
Cancer research
Chemistry
Hepatocellular carcinoma
Biochemistry
Biology
Cell biology
Medicine
Sorafenib
CXCR4
Cancer
Cancer cell
Chemokine
Downregulation and upregulation
Fibrosis
Gene
Genetics
Hepatic fibrosis
Internal medicine
Kinase
Liver cancer
MAPK/ERK pathway
MEK inhibitor
Pharmacology
Receptor
Tumor cells
Tumor microenvironment